CClinicalTrials.gg
CompletedNCT04166175professorUpdated Nov 21, 2019

High Dose Multiple Site Injection of Botox Versus Lateral Sphincterotomy in Chronic Analfissure

An interventional study of botox injection in intersphincteric space and lateral internal sphincterotomy in Chronic Anal Fissure, sponsored by Zagazig University. Completed at 1 site in Egypt. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2019-11-21.

Sponsored by Zagazig University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 5 months after the study started (first participant enrolled Jun 2017, registered Nov 2019).
Phase
Not applicable
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Study summary

comparison between the effect of lateral sphincterotomy against high dose botox injection in chronic anal fissure the outcome was healing time, recurrence continence relapse pain pruritus

Read the detailed description

This randomized comparative clinical trial was carried out over 2 year in the period between January 2018 and December 2019 on total number of 96 patients suffering chronic anal fissure the participants were randomly allocated into two groups each 48 patients ; group (1) the botulinum ( Botox) group, they were subjected to 80 IU Botox injection as an intervention for treatment of chronic anal sphincter, and group 2 the sphincterotomy group, underwent internal sphincterotomy as a surgical intervention for treatment of chronic anal fissure.

The study was approved by the institutional review board and the local ethical committee of our university hospital The condition of the current study is chronic anal fissure defined as the presence of anterior or posterior chronic anal wound with skin tag at its lower end and hypertrophied anal papilla at its upper end with induration around its edges in patients complaining of anal pain, constipation, and/or fresh anal bleeding for at least two months.

Randomization was achieved using computer generated cards. Inclusion criteria; patients suffering chronic anal fissure aged above 16 years old Exclusion criteria; those with previous anal surgery, complicated anal fissure, unfit for surgery, specific disease as Crohn's disease and ulcerative colitis, malignancy, anal fistula or abscess those with systemic disease requiring treatment with calcium channel blockers and /or nitrates Patients of both groups were subjected to thorough history taking, clinical examination, digital rectal examination and anorectal manometry for diagnosis of chronic anal fissure and exclusion of any other anal condition and incontinence, patient signed an informed written consent, routine preoperative investigations performed as usual.

Interventions;

  1. Botulinum toxin (Botox) injection; was performed under general anesthesia in the lithotomy position, where 80 IU of Botox was injected in four positions each 20 IU namely in 5, 7, 11, and 1 O'clock positions in the intersphincteric space not deeper than the midpoint of the anal canal.
  2. Lateral internal sphincterotomy; was performed under general anesthesia where the lower part of the internal sphincter was cut by electrocautery on the left lateral position to an extent not beyond the proximal end of the fissure, the sentinel pile was also removed.

After the procedure patients were advised for bulking agents, stool softener, and sitz baths The follow up was carried out in the outpatient clinic by the attending surgeon (not a study participant) after 1 week then 1, 2, 3, 6, 9 and 12 months post-procedure.

The primary outcome of the current study is complete healing of the chronic anal fissure, recurrence in the follow up time, and development of incontinence, incontinence is described as in (the Cleveland Clinic Florida-Fecal Incontinence (CCF-FI) scoring system), which contains 5 questions on solid and liquid stool leakage, gas leakage, pad use, and lifestyle restriction. the secondary outcome is postoperative or post-injection pain measured by visual analogue scale (VAS) and the time taken for complete healing of fissure (defined as complete epithelialization of the fissure).

Demographic data, presentation data, follow up data including primary and secondary outcome all collected and analyzed properly using t test, chi square test, and Z test in SPSS program 22 version.

02

Conditions studied

  • Chronic Anal Fissure

Browse trials for

03

In context

Fissure in Ano

79 studies on the registry are indexed under Fissure in Ano; 14 are open to participants now.

This study's enrollment of 96 is close to the median of 99 across 61 interventional studies indexed under Fissure in Ano.

Browse Fissure in Ano studies →

Lead sponsor

Zagazig University is the lead sponsor of 447 studies on the registry; 75 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • patients suffering chronic anal fissure aged above 16 years old

Exclusion criteria

Exclusion Criteria:

  • those with previous anal surgery,
  • complicated anal fissure,
  • unfit for surgery,
  • specific disease as Crohn's disease and ulcerative colitis,
  • malignancy,
  • anal fistula or abscess
  • those with systemic disease requiring treatment with calcium channel blockers and /or nitrates
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
96 participants (actual)

Study arms

  • Active comparator
    group 1 botox group

    48 patients subjected to 80 IU botox injection under GAin lithotomy position in the 5,7,11, and 1 O'clock positions

    Procedure: botox injection in intersphincteric space

  • Active comparator
    group 2 lateral sphincterotomy group

    48 patients subjected to lateral internal sphincterotomy under GAin lithotomy position

    Procedure: lateral internal sphincterotomy

Interventions

  • Procedurebotox injection in intersphincteric space

    injection of 80 IU of botox in the intersphincteric space in 5,7,11 and 1 O'clock position

  • Procedurelateral internal sphincterotomy

    lateral internal sphincterotomy under GA in lithotomy position

06

What researchers measure

Primary outcomes

  1. complete healing of fissure

    complete epithelialization of the floor of the chronic anal wound achieved through clinical examination at follow up visits

    Time frame: 2 months

  2. loss of anal continence

    inability to control stool or flatus measured by modified wexner score questionaire

    Time frame: 1 week

  3. recurrence

    the anal fissure reformed again after complete healing measured by clinical examination

    Time frame: 1 year

Secondary outcomes

  1. time taken for complete healing

    time taken for complete epithelialization of the anal wound measured by clinical examination

    Time frame: 1 year

  2. post operative pain

    pain in the postoperative time measured by visual analogue scale

    Time frame: 1 month

07

Study locations

1 site
  • Zagazig Faculty of Medicine
    Zagazig, Sharqya 44519, Egypt
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 21, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04166175
Lead sponsor
Zagazig University
Responsible party
Hazem Nour Abdellatif (Assistant professor, Zagazig University) — Principal investigator
First posted
Nov 18, 2019
Start date
Jun 1, 2017
Primary completion
May 30, 2019
Completion
May 30, 2019
Last update
Nov 21, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion